ÂÜÀòÂÒÂ×

Dr. Orbach is the Head of the Pharma Division of Arkin Holdings and a member of the board at several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics - a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. He holds a PhD from the University of Florida, and was a postdoctoral fellow at Harvard Medical School - Massachusetts General Hospital.